Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks.com reports.

Several other brokerages have also recently commented on BAYRY. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Morgan Stanley upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. DZ Bank downgraded Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research note on Wednesday, February 18th. Finally, UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Down 0.1%

Bayer Aktiengesellschaft stock opened at $10.97 on Tuesday. The stock has a market cap of $43.11 billion, a price-to-earnings ratio of -9.88 and a beta of 0.69. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10. The company’s 50-day moving average price is $12.41 and its two-hundred day moving average price is $10.19. Bayer Aktiengesellschaft has a 52 week low of $5.30 and a 52 week high of $14.85.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.18. The company had revenue of $13.24 billion during the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts expect that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.